Thao Kim Huynh, PharmD | Authors


IDH Mutations Offer Hope as a Prognostic Indicator and Treatable Target in Gliomas

July 17, 2019

Several presentations at the 2019 American Society of Clinical Oncology Annual Meeting highlighted a hopeful new direction in the treatment of gliomas, demonstrating the relevance of IDH1/2 mutational status and its feasibility as a target of therapy.